Given that NACA was able to counteract the effects of the ACOX1 gain-of-function mutation, antioxidant treatment was considered for patient#1 during a severe disease flare
Khi collagen khng , tc c th tr nn mng manh v d gy, trong khi mng c th tr nn gin v d v
However, the tirzepatide combination has the advantage of using an FDA-approved base compound with extensive safety data
metabolites in cluster 6 (decreased in the papain group uniquely) were enriched in taurine and hypotaurine metabolism and alanine aspartate and glutamate metabolism, implying systemic dysregulation of antioxidant defense mechanisms (Figures 3FH)
B., Novellino, E., Antolak, H., Azzini, E., Setzer, W